J
Juniper Biosciences
Radiopharmaceutical drug development for imaging and therapy
About Juniper Biosciences
Juniper Biosciences is a drug development company focused on radiopharmaceuticals. The company aims to improve patient access to new therapeutic and diagnostic medicines for cancer and other diseases.
The company was founded by Chief Executive Officer (CEO) Alex Agnoletto, Chief Operating Officer (COO) Dr. Indranil Nandi, and Director of Manufacturing Dr. Kyle Hoffmann. The leadership team has extensive experience in the global radiopharmaceutical development and manufacturing sectors. Before co-founding Juniper Biosciences, Agnoletto was the CFO at Evergreen Theragnostics, Nandi was the CSO at Jubilant Radiopharma, and Hoffmann was the VP, Site Head, and RSO at Evergreen Theragnostics.
Juniper Biosciences' business model centers on advancing a pipeline of radiopharmaceutical agents for various diseases. The company harnesses radioisotopes linked to high-specificity ligands to enable earlier disease diagnosis and more effective treatment, with the goal of minimizing side effects and maximizing therapeutic impact. While its current development pipeline is confidential, it includes several assets in different stages of development. In December 2025, the company announced it had raised $40 million in an oversubscribed seed financing round to fund the development of its pipeline. The financing was co-led by NovaCapital, private high-net-worth individuals, and members of the Club Degli Investitori.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- Bedminster Township, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 88.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Oncology, Drug Development, Spinout, Radioisotope Therapeutics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Dec 2025 | $40M | $160M | Novacapital | ↗ |
| SPINOUT✓Other financing | Jan 2025 | $0 | — | Memorial Sloan - Kettering Cancer Center | — |
Growth signals
Latest recorded traffic for Juniper Biosciences is 1.2K monthly website visits, up 37.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Novacapital
Other known investors1 additional known investor
Memorial Sloan - Kettering Cancer Center
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Juniper Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Juniper Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.